It’s August 2009 and in the last 12 months, Lou Bock‘s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture [See the full post…]

Capital efficiency and regulatory hurdles are the two main challenges for investing in healthcare today. Scale Venture Partners Managing Director, Lou Bock shares these insights as well as discussing what is most important to him in an investment today. [See the full post…]